Zacks Investment Research Upgrades Amicus Therapeutics, Inc. (FOLD) to Hold
Amicus Therapeutics, Inc. (NASDAQ:FOLD) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued on Wednesday.
According to Zacks, “AMICUS THERAPEUTICS is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilize proteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus has completed Phase 2 clinical trials of Amigal(TM) for the treatment of Fabry disease and is conducting Phase 2 clinical trials of Plicera(TM) for the treatment of Gaucher disease. “
Several other brokerages also recently commented on FOLD. BidaskClub upgraded Amicus Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Wednesday. Robert W. Baird boosted their price objective on Amicus Therapeutics from $12.00 to $15.00 and gave the company an “outperform” rating in a research report on Wednesday, July 12th. Cowen and Company restated a “buy” rating and issued a $16.00 price objective (up from $10.00) on shares of Amicus Therapeutics in a research report on Tuesday, July 11th. ValuEngine upgraded Amicus Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, June 9th. Finally, JPMorgan Chase & Co. set a $13.00 price objective on Amicus Therapeutics and gave the company a “buy” rating in a research report on Monday, June 5th. Two research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $12.46.
Shares of Amicus Therapeutics (FOLD) traded down 3.19% during mid-day trading on Wednesday, reaching $13.37. The company had a trading volume of 5,257,934 shares. The firm has a 50 day moving average of $10.10 and a 200-day moving average of $7.61. The stock’s market capitalization is $1.91 billion. Amicus Therapeutics has a one year low of $4.41 and a one year high of $14.05.
Amicus Therapeutics (NASDAQ:FOLD) last announced its quarterly earnings data on Tuesday, May 9th. The biopharmaceutical company reported ($0.39) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.37) by $0.02. The firm had revenue of $4.20 million during the quarter, compared to analyst estimates of $4.16 million. The company’s quarterly revenue was up 50.0% compared to the same quarter last year. Analysts forecast that Amicus Therapeutics will post ($1.44) EPS for the current fiscal year.
WARNING: “Zacks Investment Research Upgrades Amicus Therapeutics, Inc. (FOLD) to Hold” was published by American Banking News and is the sole property of of American Banking News. If you are reading this article on another publication, it was stolen and reposted in violation of United States & international copyright laws. The correct version of this article can be viewed at https://www.americanbankingnews.com/2017/07/19/zacks-investment-research-upgrades-amicus-therapeutics-inc-fold-to-hold.html.
In other Amicus Therapeutics news, insider Jay Barth sold 30,000 shares of the business’s stock in a transaction that occurred on Monday, June 19th. The stock was sold at an average price of $10.00, for a total transaction of $300,000.00. Following the sale, the insider now directly owns 64,184 shares of the company’s stock, valued at $641,840. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Life Sciences Maste Perceptive acquired 1,500,000 shares of Amicus Therapeutics stock in a transaction on Thursday, July 13th. The shares were bought at an average cost of $12.25 per share, for a total transaction of $18,375,000.00. The disclosure for this purchase can be found here. 3.40% of the stock is currently owned by insiders.
Large investors have recently modified their holdings of the company. Principal Financial Group Inc. boosted its stake in shares of Amicus Therapeutics by 1.8% in the first quarter. Principal Financial Group Inc. now owns 26,883 shares of the biopharmaceutical company’s stock valued at $192,000 after buying an additional 487 shares during the last quarter. KCG Holdings Inc. boosted its stake in shares of Amicus Therapeutics by 1.1% in the first quarter. KCG Holdings Inc. now owns 66,066 shares of the biopharmaceutical company’s stock valued at $471,000 after buying an additional 743 shares during the last quarter. Aperio Group LLC boosted its stake in shares of Amicus Therapeutics by 13.5% in the second quarter. Aperio Group LLC now owns 13,986 shares of the biopharmaceutical company’s stock valued at $141,000 after buying an additional 1,663 shares during the last quarter. Metropolitan Life Insurance Co. NY boosted its stake in shares of Amicus Therapeutics by 5.2% in the first quarter. Metropolitan Life Insurance Co. NY now owns 102,462 shares of the biopharmaceutical company’s stock valued at $731,000 after buying an additional 5,041 shares during the last quarter. Finally, Creative Planning boosted its stake in shares of Amicus Therapeutics by 56.2% in the first quarter. Creative Planning now owns 16,400 shares of the biopharmaceutical company’s stock valued at $117,000 after buying an additional 5,900 shares during the last quarter.
Amicus Therapeutics Company Profile
Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Amicus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.